308 related articles for article (PubMed ID: 12941841)
1. Melanoma differentiation-associated gene 7/interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor.
Ramesh R; Mhashilkar AM; Tanaka F; Saito Y; Branch CD; Sieger K; Mumm JB; Stewart AL; Boquoi A; Dumoutier L; Grimm EA; Renauld JC; Kotenko S; Chada S
Cancer Res; 2003 Aug; 63(16):5105-13. PubMed ID: 12941841
[TBL] [Abstract][Full Text] [Related]
2. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
3. Bystander activity of Ad-mda7: human MDA-7 protein kills melanoma cells via an IL-20 receptor-dependent but STAT3-independent mechanism.
Chada S; Mhashilkar AM; Ramesh R; Mumm JB; Sutton RB; Bocangel D; Zheng M; Grimm EA; Ekmekcioglu S
Mol Ther; 2004 Dec; 10(6):1085-95. PubMed ID: 15564140
[TBL] [Abstract][Full Text] [Related]
4. Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12.
Wong RJ; Chan MK; Yu Z; Ghossein RA; Ngai I; Adusumilli PS; Stiles BM; Shah JP; Singh B; Fong Y
Clin Cancer Res; 2004 Jul; 10(13):4509-16. PubMed ID: 15240543
[TBL] [Abstract][Full Text] [Related]
5. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
Laird AD; Vajkoczy P; Shawver LK; Thurnher A; Liang C; Mohammadi M; Schlessinger J; Ullrich A; Hubbard SR; Blake RA; Fong TA; Strawn LM; Sun L; Tang C; Hawtin R; Tang F; Shenoy N; Hirth KP; McMahon G; Cherrington
Cancer Res; 2000 Aug; 60(15):4152-60. PubMed ID: 10945623
[TBL] [Abstract][Full Text] [Related]
6. Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Cao Z; Baguley BC; Ching LM
Cancer Res; 2001 Feb; 61(4):1517-21. PubMed ID: 11245459
[TBL] [Abstract][Full Text] [Related]
7. N-myc oncogene overexpression down-regulates IL-6; evidence that IL-6 inhibits angiogenesis and suppresses neuroblastoma tumor growth.
Hatzi E; Murphy C; Zoephel A; Rasmussen H; Morbidelli L; Ahorn H; Kunisada K; Tontsch U; Klenk M; Yamauchi-Takihara K; Ziche M; Rofstad EK; Schweigerer L; Fotsis T
Oncogene; 2002 May; 21(22):3552-61. PubMed ID: 12032857
[TBL] [Abstract][Full Text] [Related]
8. Angiosuppressive and angiostimulatory effects exerted by synthetic partial sequences of endostatin.
Morbidelli L; Donnini S; Chillemi F; Giachetti A; Ziche M
Clin Cancer Res; 2003 Nov; 9(14):5358-69. PubMed ID: 14614021
[TBL] [Abstract][Full Text] [Related]
9. Prolactin antagonist-endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer.
Beck MT; Chen NY; Franek KJ; Chen WY
Cancer Res; 2003 Jul; 63(13):3598-604. PubMed ID: 12839947
[TBL] [Abstract][Full Text] [Related]
10. Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties.
Huang EY; Madireddi MT; Gopalkrishnan RV; Leszczyniecka M; Su Z; Lebedeva IV; Kang D; Jiang H; Lin JJ; Alexandre D; Chen Y; Vozhilla N; Mei MX; Christiansen KA; Sivo F; Goldstein NI; Mhashilkar AB; Chada S; Huberman E; Pestka S; Fisher PB
Oncogene; 2001 Oct; 20(48):7051-63. PubMed ID: 11704829
[TBL] [Abstract][Full Text] [Related]
11. Studies on the structure-activity relationship of endostatin: synthesis of human endostatin peptides exhibiting potent antiangiogenic activities.
Chillemi F; Francescato P; Ragg E; Cattaneo MG; Pola S; Vicentini L
J Med Chem; 2003 Sep; 46(19):4165-72. PubMed ID: 12954068
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway.
Wei LH; Kuo ML; Chen CA; Chou CH; Lai KB; Lee CN; Hsieh CY
Oncogene; 2003 Mar; 22(10):1517-27. PubMed ID: 12629515
[TBL] [Abstract][Full Text] [Related]
13. Activin A suppresses neuroblastoma xenograft tumor growth via antimitotic and antiangiogenic mechanisms.
Panopoulou E; Murphy C; Rasmussen H; Bagli E; Rofstad EK; Fotsis T
Cancer Res; 2005 Mar; 65(5):1877-86. PubMed ID: 15753386
[TBL] [Abstract][Full Text] [Related]
14. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
Bae DG; Kim TD; Li G; Yoon WH; Chae CB
Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of endothelial cell differentiation and proinflammatory cytokine production during angiogenesis by allyl isothiocyanate and phenyl isothiocyanate.
Thejass P; Kuttan G
Integr Cancer Ther; 2007 Dec; 6(4):389-99. PubMed ID: 18048887
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of angiostatin, endostatin and interferon-alpha(1) gene transfer on in vivo growth of human breast cancer cells.
Indraccolo S; Gola E; Rosato A; Minuzzo S; Habeler W; Tisato V; Roni V; Esposito G; Morini M; Albini A; Noonan DM; Ferrantini M; Amadori A; Chieco-Bianchi L
Gene Ther; 2002 Jul; 9(13):867-78. PubMed ID: 12080381
[TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
[TBL] [Abstract][Full Text] [Related]
18. mda-7/IL-24, novel anticancer cytokine: focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (Review).
Lebedeva IV; Emdad L; Su ZZ; Gupta P; Sauane M; Sarkar D; Staudt MR; Liu SJ; Taher MM; Xiao R; Barral P; Lee SG; Wang D; Vozhilla N; Park ES; Chatman L; Boukerche H; Ramesh R; Inoue S; Chada S; Li R; De Pass AL; Mahasreshti PJ; Dmitriev IP; Curiel DT; Yacoub A; Grant S; Dent P; Senzer N; Nemunaitis JJ; Fisher PB
Int J Oncol; 2007 Nov; 31(5):985-1007. PubMed ID: 17912425
[TBL] [Abstract][Full Text] [Related]
19. The transforming growth factor-beta family members bone morphogenetic protein-2 and macrophage inhibitory cytokine-1 as mediators of the antiangiogenic activity of N-(4-hydroxyphenyl)retinamide.
Ferrari N; Pfeffer U; Dell'Eva R; Ambrosini C; Noonan DM; Albini A
Clin Cancer Res; 2005 Jun; 11(12):4610-9. PubMed ID: 15958647
[TBL] [Abstract][Full Text] [Related]
20. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
